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Transport proteins are essential for cells in allowing the exchange of substances between cells 
and their environment across the lipid bilayer forming a tight barrier. Membrane lipids 
modulate the function of transmembrane proteins such as transporters in two ways: Lipids are 
tightly and specifically bound to transport proteins and in addition they modulate from the bulk 
of the lipid bilayer the function of transport proteins. This overview summarizes currently 
available information at the ultrastructural level on lipids tightly bound to transport proteins 
and the impact of altered bulk membrane lipid composition. Human diseases leading to altered 
lipid homeostasis will lead to altered membrane lipid composition, which in turn affect the 




Cellular membranes are of critical importance for all kingdoms of life as they form the 
boundaries between different compartments within a cell and between cells. The evolutionary 
origin of membranes is elusive and a matter of debate [1], but modern life has three essential 
interdependent building blocks: metabolic machineries, genetic and/or template information 
and compartmentalization maintained by membranes [2]. The compartmentalization allows 
highly divergent biological processes such as supplying energy by mitochondria and "waste" 
processing by lysosomes to occur in parallel in a cell. Moreover, membranes separate units of 
life from their environment. As the conditions within as well as outside of compartments are 
constantly changing, membranes need to be able to transmit information between 
compartments as well as exchanging substances between compartments. The basic constituents 
of biological membranes are lipids, proteins and sugars in form of glycolipids and post-
translationally modified proteins [3]. The basic model of a biological membrane is the unit 
membrane introduced by Robertson as reviewed in [4] and consists of a triple-layered structure 
with a hydrophobic core between two hydrophilic surfaces. The accepted model of a unit 
membrane today is the so called "fluid mosaic model" introduced by Singer and Nicolson in 
1972 [5], which is taking into account the lateral mobility of lipids as well as proteins in 
membranes. The glycerophospholipids are the main lipid constituent and are arranged in a tail-
to-tail configuration. The hydrophobic core of the lipid bilayer of biological membranes formed 
by the fatty acids is providing the barrier function of biological membranes [6, 7]. The 
possibilities of lipid analysis have made tremendous progress in the recent past, both in the area 
of instrumentation as well as in the area of computational approaches for data handling and 
analysis [8, 9]. Today, there are thousands of different lipids known [10]. This fascinating 
diversity of lipids allows cells and consequently organisms to respond to changes in 
homeostasis as well as inputs from the environment. Post-translational modification of 
transporters and its functional implications has been studied intensively [11]. However, the 
knowledge on the role and impact of membrane lipids on transporter function is not yet fully 
explored. The aim of this overview therefore is to give an overview on findings on lipids tightly 
bound to transporters from protein structural studies and on the current knowledge on the 
impact of membrane lipid composition on transporter function. 
 
Membrane Lipid Composition 
As different membranes (also within the same cell) have different functions, the lipid 
composition of membranes varies considerably [6, 7, 12]. In brief [13](figure 1): Within an 




and at the same time forms a continuum with the endoplasmic reticulum. The endoplasmic 
reticulum is the synthetic site for membrane and secreted proteins as well as an important 
organelle involved in cellular responses to stress [14, 15]. The endoplasmic reticulum is also 
the major organelle for lipid biosynthesis [6, 7]. While cholesterol synthesis starts at the 
endoplasmic reticulum, it is rapidly leaving this organelle and is following the biosynthetic 
path of membranes to the cell surface, where it is found at a higher relative amount [16] (figure 
2). Hence, the endoplasmic reticulum can be view as the assembly site of cellular membranes. 
The endoplasmic reticulum is in exchange with other cellular organelles by a brisk traffic of 
membrane vesicles moving from or to the endoplasmic reticulum [17]. This vesicular flux is 
complemented by phospholipid transfer proteins mediating also exchange of phospholipids 
between cellular compartments [18, 19]. The Golgi apparatus puts the finish on newly 
synthesized membrane proteins and is also a repair system for membrane proteins of the plasma 
membrane [20]. The plasma membrane is the final destination for many membrane proteins 
and lipids. Functionally, the lipid composition of subcellular membranes needs to adapt from 
the endoplasmic reticulum to the plasma membrane from a biosynthetic to a barrier function 
[21]. This route of newly synthesized proteins and lipids from the endoplasmic reticulum to 
the plasma membrane has a counterpart: Endocytosis is directed in an opposite direction from 
the plasma membrane towards the interior of the cell [22]. In polarized cells, endocytosis also 
continues into transcytosis, which is a vesicular route crossing cells [23]. The membrane flux 
through these routes with opposing and intersecting directions requires extensive sorting and 
regulation [24]. These very different functions of subcellular membranes are reflected by their 
different lipid compositions [6, 7, 25]. At a higher level, this complex pattern of lipid specificity 
is topped at the level of organisms by different lipid compositions of different cell types 
fulfilling very diverse functions [26]. 
 
Lipids have been defined "as hydrophobic or amphipathic small molecules that may originate 
entirely or in part by carbanion-based condensations of thioesters (fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, saccharolipids, and polyketides) and/or by carbocation-
based condensations of isoprene units (prenol lipids and sterol lipids)" [27] and can be divided 
into eight categories. Membrane lipids are distinguished into four [28] or three [7] categories 
glycerophospholipids, sphingolipids, sterols and glycolipids as minor component. 
Glycerophospholipids are derived from glycerol 3-phosphate, while sphingolipids are derived 
from sphingosine. The prototypic structure of sterols is cholesterol, which is also the major 




sphingolipids containing sugars and are typically found in the outer leaflet. The large variety 
of different lipids [10, 27] originates from are large number of different fatty acids and their 
combination as substituents of the major lipid backbones. 
 
 
Lipids tightly bound to membrane proteins 
Lipids interact at different levels with membrane proteins [29] (figure 3): Annular or boundary 
lipids are viewed as a single shell of lipids directly interacting with the membrane protein. This 
interaction may be very defined, e.g. by lipids found in clefts on the surface of the protein, 
occupying space between transmembrane helices or "sitting" on hydrophobic protein surfaces. 
Lipids may also exert an interaction with membrane proteins at distance, which can be observed 
as different molar lipid to protein ratios in a membrane [29]. Studying lipids tightly bound to 
membrane proteins requires structural studies at a resolution sufficient to identify lipids or at 
least identification of lipids of highly purified membrane proteins by analytical tools. Studying 
the impact of bulk membrane lipids necessitates the isolation of highly purified fractions of the 
membranes of interest followed by lipid analysis. 
 
The basic definition of solute transport is movement of a dissolved molecule from one 
compartment to another compartment, which are separated from each other by a biological 
membrane. The term solute implies that the molecule of interest is in a solution, which in 
biology is aqueous. Transport in biology is with rare exceptions (e.g. O2) mediated by 
transmembrane proteins. Parenthetically it is currently debated whether aquaporins act as 
proteins facilitating O2 movement across biological membranes [30]. Solute transport proteins 
are classified into SLC transporters, primary active ATP-dependent transporters (P-type 
ATPases and ABC transporters) and channels [31]. Investigating the direct interaction of lipids 
with transporters requires detailed knowledge on the protein structure. Detailed structural 
information on membrane proteins started to emerge in the mid1980s, when the crystal 
structure of bacteriorhodopsin was resolved [32, 33]. Bacteriorhodopsin can be viewed as a 
transporter, as it uses the energy of light for moving protons against a concentration gradient 
across a bacterial membrane. Following the transport definition given above, ion channels are 
transport proteins [31]. Consequently, the first structure of a bacterial membrane protein (porin) 
acting as a channel was published in 1991 [34] followed by the ferrichrome receptor/transporter 
[35]. In 1998 the structure of a bacterial homologue of a mammalian potassium channel was 




concentration gradient, was the first primary active transporter known structurally [37]. The 
first ABC transporter architecture was published in 2002 [38]. The first major facilitator 
structures were published in 2003 [39] including the co-transporter lactose permease [40]. 
These early structural studies of membrane proteins did not address the issue of lipids tightly 
bound to the investigated proteins. 
 
The human genome encodes for more than 90 P-type ATPases [41]. The crystal structure of 
mammalian of (Na++K+)-ATPase was reported to contain a phosphatidylcholine tightly bound 
-helix [42]. Later it was observed that the structure of (Na++K+)-ATPase crystalized 
from the rectal gland of spiny dogfish contained at the same position a tightly bound 
cholesterol, which was carried to the structure determination of the purified protein from the 
native enzyme in the tissue used for isolation [43]. 
 
In human tissues, 48 ABC proteins are expressed, most of which are transporters [44]. Several 
laboratories published structures of MDR1 (also called P-glycoprotein). To the best of our 
knowledge, only one of the publications addressed the issue of lipids tightly bound to human 
MDR1 [45]. These authors observed at the level of the outer leaflet a ring of ordered cholesterol 
(figure 5A). At the level of the inner leaflet, tightly bound lipids were identified as 
phosphatidylethanolamines as well as cholesterol. A potential functional role of the tightly 
bound phospholipids in MDR1 function is supported by findings that 
phosphatidylethanolamine strongly stimulates the ATPase activity of partially purified MDR1 
in a reconstituted system [46]. Whether the tightly bound cholesterol molecules are indeed 
solely responsible for the modulation of the ATPase and transport activity of MDR1 [47, 48] 
remains to be experimentally demonstrated. Further, an additional model for the role of 
cholesterol in MDR1 transport has been proposed: the so called cholesterol fill-in model takes 
the rather large substrate binding site of MDR1 into account and suggest that cholesterol, by 
"filling" the binding pocket in addition to small substrate exerts the observed stimulation [49]. 
The cryogenic electron microscopy (cryo-EM) structure of ABCG2 indeed contained two 
cholesterol molecules located at the substrate binding site of this multidrug exporter [50]. 
Comparable to MDR1, ABCG2 is also surrounded by a belt of tightly bound phospholipids, 
namely five phosphatidylethanolamines as well as five cholesterol molecules (figure 5B) [51]. 
Here, the lipids are located at the outer surface of the homodimer, but not between the subunits. 
It is premature at this state of knowledge to make detailed statements about the interaction of 




lipids are clearly observed in indentations at the protein surface. It should also be noted that no 
lipids intercalating with the transmembrane helices were identified in these two proteins (figure 
5). A tight interaction of lipids with ABC transporters is not restricted to the plasma membrane. 
The structure of the mitochondrial transporter ABCB10 contains tightly bound cardiolipin, a 
lipid restricted to mitochondria [52]. Taken together, there is now plenty of structural evidence 
available that transport proteins utilizing ATP as energy source contain tightly bound 
phospholipids and cholesterol. 
 
Currently, over 450 transporters belonging to the SLC superfamily of transporters are known 
in humans [54]. The structure of the Drosophila melanogaster dopamine transporter (DAT; 
SLC6A3) displays a tightly bound cholesterol molecule in a groove between TM5 and TM7 
[55]. Similarly, the transporter mediating the transport of the human neurotransmitter serotonin 
(SERT; SLC6A4) binds tightly cholesterol hemisuccinate, which in vivo may be a binding site 
for cholesterol [56]. A tightly bound cholesterol hemisuccinate was also identified in the human 
glutamine transporter (ASCT2, SLC1A5) [57]. The recent cryo-EM structure of the human L-
type amino acid transporter (SLC7A5) in complex with SLC3A2 shows several tightly bound 
cholesterol molecules, which may also be involved in the interaction of the two subunits of this 
transporter [58]. The crystal structure of the mitochondrial ADP/ATP exchanger from beef 
heart has been shown tightly binding two cardiolipins, a lipid only found in mitochondria [59] 
and in a follow up crystal structure three cardiolipin molecules [60]. Hence, tightly bound lipids 
are not only "simple" but also complex glycerophospholipds. The list of bacterial transporters 
containing tightly bound lipids is considerable [61] and using mass spectrometry as a new tool 
for the investigation of the interaction membrane proteins with tightly bound lipids offers a 
new and exciting possibility for expanding this list further [28]. TMEM16K is a lipid 
scramblase residing in the endoplasmic reticulum and its function requires a transient, tight 
interaction with phospholipids. Interestingly, this scramblase also contains tightly bound, yet 
unidentified lipids at the boundary of the protein and the membrane of the endoplasmic 
reticulum [53]. 
 
Channels are the third class of transporters and over 310 genes coding for channels are currently 
known in humans [31]. Potassium inwardly rectifying (Kir) channels interact with 
phosphatidylinositol 4,5-bisphosphonate (PIP2), which in turn acts as an agonist on these 
channels [62]. The determination of the X-ray crystal structure of chicken Kir 2.2 bound with 




The binding site is located at the interface between the transmembrane and the cytoplasmic 
domain and binding of PIP2 induces a large change in conformation by tethering the 
cytoplasmic domain to the transmembrane domain, which actives the channel. The ammonia 
channel (AmtB) from Escherichia coli was found binding eight phosphatidylglycerol 
molecules, while a ninth molecule could not be definitively identified [64]. Cryo-EM analysis 
of the human voltage-gated Nav revealed densities of four phospholipid 
molecules bound to the pore- -subunit [65]. The authors interpreted three additional 
linear densities traversing fenestrations of the pore subunit as lipids. Similarly, the cryo-EM 
structure of a human voltage gated calcium channel, Cav3.1, which was engineered as a 
corresponding splice variant of a rat Cav.1 lacking the linker between domains I and II also 
identified transverse lipids in the pore domain [66]. Bacterial voltage-gated sodium channels 
(NaChBac) are likely evolutionary ancestors of mammalian voltage-gated sodium channels 
[67] and also contain multiple tightly bound lipids at the transmembrane domain[68]. Transient 




Taken together, as cryo-EM technology nurtures a rapidly expanding list of transport and other 
membrane protein structures [70, 71], the information of tightly bound lipids to such 
transporters is rapidly growing as well. For example, the purified transporter associated with 
antigen processing (TAP) (ABCB2/ABCB3) was found to be associated with several different 
phospholipids [72]. 
 
Lipid Dependent Modulation of Transport Protein Activity 
As outlined above, the identification of tightly bound lipids to transport proteins as well as 
other membrane proteins requires knowledge of the structure of the proteins of interest and 
their direct surroundings. This information should be complemented and detailed to the atomic 
level of highly purified membrane proteins by the application of mass spectrometry. Since both 
approaches require highly specialized and sophisticated equipment as well as technically 
challenging procedures, the impact of lipid modulation on the function of membrane proteins 
like transporters is so far often investigated at the bulk level where membrane lipid analysis is 





The investigation of the role of lipids on membrane protein function started by modifying the 
lipid composition of the membrane in which the protein of interest is expressed. (Na++K+)-
ATPase is a P-type ATPase and as such a prototypic primary active transporter, which is in 
addition key for providing the energy source for secondary active transporters [73]. The activity 
of (Na++K+)-ATPase of erythrocytes from rats fed with different fat diets was found to depend 
on erythrocyte membrane fatty acid composition [74] as well as on cholesterol content [75] of 
red cell membranes. Working with (Na++K+)-ATPase from bovine kidney, a bell-shaped 
dependence of the activity of this transporter on membrane cholesterol content was reported 
[76]. A study working with shark rectal gland (Na++K+)-ATPase reconstituted in 
proteoliposomes revealed that the enzymatic activity was both a function of the cholesterol 
content and the acyl chain length of the phospholipids [77, 78]. In the absence of cholesterol 
the maximal turnover rate was at an acyl chain length of 22, while in the presence of 40 mol% 
cholesterol, the acyl chain length for maximal turnover rate decreased to 18. Another study 
found the dependence of the ATPase activity from porcine kidney on membrane thickness by 
a method known to alter membrane thickness [79]. However, the thickness of the membrane 
was not experimentally determined in this study. While is seems intuitive that increasing acyl 
chain length increases membrane thickness, this has not been verified experimentally as a 
general rule. Rather it was observed that the area occupied by a phospholipid molecule 
increases more than the thickness of the bilayer when the acyl chain length is increased [80]. 
In addition, it should be kept in mind that the hydrophobic surface of a membrane protein exerts 
a force on the lipid bilayer and can induce local curvatures in the lipid bilayer. Lipids in the 
bilayer on the other hand can counteract such structural changes and thereby exert a force on 
the membrane protein [81, 82]. Consequently, there is a complex and mutual biophysical 
interaction between membrane lipids and membrane proteins. 
 
P-type ATPases reside in all cellular membranes [83]. Reconstitution of sarcoplasmic 
reticulum Ca2+-ATPase into proteoliposomes demonstrated a dependence of its transport 
activity on the phosphatidylethanolamine content [84]. The effects of lipids on Ca2+-ATPase 
were found to be cooperative: The activity of this transporter is lower when reconstituted in a 
phosphatidylethanolamine membrane than in a membrane composed of phosphatidylcholine. 
However, in a mixture of the two phospholipids, the portion of phosphatidylethanolamine 
needs to exceed 80 mol% to reduce the ATPase activity of the reconstituted Ca2+-ATPase [85]. 
However, at contents higher than 75 % of phosphatidylethanolamine, the lipid forms a 




the activity of Ca2+-ATPase. In addition to affecting the activity [86], the chain length of 
phosphatidylcholine affects the stoichiometry of Ca2+ binding to sarcoplasmic reticulum Ca2+-
ATPase [87]. These lipid effects are not restricted to the isoform of Ca2+-ATPase expressed in 
the sarcoplasmic reticulum. Ca2+-ATPase purified from human erythrocyte membranes and 
reconstituted into proteoliposomes is also regulated by various phospholipids, which affect 
both, Vmax and Km [88]. 
 
ABC transporters are another very important superfamily of primary active transporters [31]. 
MDR1 is known to be very sensitive to its lipid environment, as this transporter loses its activity 
if deprived from lipids during purification [89, 90]. Drug binding is also depending on the type 
of phospholipids used [91]. Drug binding to purified MDR1 reconstituted in proteoliposomes 
shows a bell-shape dependence of relative cholesterol content [92]. Depleting cells expressing 
MDR1 from cholesterol reduced the activity of MDR1 using different substrates [93-95]. It is 
interesting to note that the ATPase activity of MDR1 reconstituted into proteoliposomes is 
lower in comparison to reconstitution into nanodiscs [96]. The exact reason for the higher basal 
ATPase rate of MDR1 in nanodiscs is unknown. Hence, the specific activity of MDR1 in both 
configurations does not differ. In 2007, three laboratories reported that the activity of ABCG2 
is stimulated by an increased membrane cholesterol content [97-99]. Using cholesterol-poor 
insect cell membranes [100] in conjunction with sterol loading, this stimulation was most 
pronounced, if not specific for cholesterol: ergosterol loading tended to reduce ABCG2 
transport activity while sitosterol and hydrocortisone had no effect [99]. This sterol-
dependence of transporter activation is different in MDR1, where next to Cholesterol 
stigmasterol, sitosterol and campesterol stimulate ATPase activity [49]. Cholesterol did not 
affect the Km values of ABCG2, but stimulated Vmax about 20-fold for methotrexate and 
stimulated Vmax for estradiol- -glucuronide about 15-fold [99]. Another group also found 
no effect of cholesterol loading on Km values, but an about 25-fold Vmax stimulation for 
esterone-3-sulfate and an about 8-fold Vmax stimulation for prazosin transport [97]. Starting 
from isolated canalicular membrane vesicles from mouse liver, cholesterol depletion showed a 
reduction of the transport activity of mBSEP and of mMRP2, illustrating again a stimulatory 
effect of cholesterol on these two ABC transporters [102]. The effect of cholesterol on the 
transport activity of the bile salt export pump BSEP was investigated using four different bile 
salts as substrate and three species: human, rat and mouse. As for ABCG2, BSEP of all three 
species was only affected by an increased Vmax but not at the Km for all bile salts tested after 




to progressive cholestasis, which progresses often to severe liver disease [104] and 
polymorphisms in the ABCB11 gene may lead to acquired cholestasis [105]. Often, BSEP 
variants are functionally characterized upon expression in insect cells. As insect cell membrane 
vesicles are a convenient tool for functionally characterizing ABC transporters [106], we 
investigated the impact of cholesterol on the function of BSEP variants [107]. The p.444A and 
the wild type BSEP variants did not change affinity to taurocholate, but had both an increased 
Vmax in high cholesterol insect membrane vesicles. The p.E297G and the p.R432T variants can 
cause cholestasis in patients and display practically no transport activity in wild type insect cell 
membrane vesicles. These two variants displayed clearly measureable transport activity after 
cholesterol loading. However they did not come near the transport activity of the wild type 
BSEP in cholesterol loaded insect cell vesicles [107]. These findings suggest that changes of 
cholesterol levels in the canalicular membrane are not an additional susceptibility factor for 
acquired (or inherited) cholestasis. This result obtained for BSEP variants could also indicate 
that reconstituting BSEP (as well as other hepatocellular ABC transporters) in lipid membranes 
of different cholesterol content for structural studies may not induce gross structural alterations. 
Studies using HepG2 cells and a functional assay for MRP2 showed that in this expression 
system MRP2 activity was dependent on cholesterol [101]. In parallel to the kinetic BSEP 
study, we also investigated the effect of membrane cholesterol on kinetic properties of MRP2. 
For all substrates, the Vmax was increased by cholesterol loading [107]. Interestingly, the effects 
on the affinity were substrate dependent: For small substrates, loading with cholesterol turned 
allosteric transport kinetics to regular Michaelis-Menten type kinetics, while for large 
substrates, the transporter showed in both conditions regular kinetics. In this context, it is 
interesting and important to note that insect Sf9 cells contain endogenous ABC transporter 
activities, which become unmasked after cholesterol loading [108]. Two potential candidate 
genes belonging to the ABCC family are found in Sf9 cells and could explain the observed 
substrate pattern: SfABCC2 and SfABCC3. Hence, in all expression systems, careful controls 
are needed when studying the impact of membrane lipid composition on (ABC) transporter 
activity. The transporter associated with antigen processing (TAP) is a heterodimer composed 
of ABCB2 and ABCB3 and resides in the endoplasmic reticulum [109]. Functional 
reconstitution of this heterodimer expressed in the yeast Pichia pastors shows a lipid 
dependence whereby the transporter was not active in phosphatidylcholine [72]. Interestingly, 
addition of cholesterol inhibited TAP activity, which may be explained by the relatively low 
cholesterol content of the endoplasmic reticulum [16] (Figure 3). Cystic fibrosis 




Investigation of the purified and reconstituted protein showed a clear dependence of the 
ATPase activity on cholesterol [111].  
 
To our knowledge, the effect of sphingolipids on the activity of ABC transporters has not been 
investigated in detail. Depleting murine neuroblastoma Neuro-2a cells from sphingolipids did 
not result in an alteration of MRP1 activity as assessed by a fluorescein efflux assay [112]. In 
the same cell line, depletion of gangliosides did also not affect the activity of MDR1 and MRP1 
[113]. We found that sphingomyelin loading of membranes with low and with high cholesterol 
content did not affect the activity of MRP2 and BSEP (Steiger and Stieger, unpublished). 
 
Tetraethylammonium is a substrate of human organic cation transporters of the SLC22A and 
SLC47A families [114]. Loading cholesterol to brush border membrane vesicles isolated from 
rat kidney resulted in both, a the dissipation rate of a H+ gradient and an increased intrinsic 
tetraethylammonium uptake (in the absence of a pH gradient) [115]. This can be interpreted 
that one (or more) of the organic cation transporters are modulated by membrane cholesterol 
content. An alternate interpretation of these findings is an altered stability of substrate gradients 
over the membrane of the vesicles. Reconstitution experiments of bovine cardiac sarcolemmal 
Na+/Ca2+ exchanger demonstrated that the addition of plasmalogen to the proteoliposomes 
massively stimulates the activity of this exchanger [116].  
 
Depleting cholesterol from membranes HEK 293 cells expressing the rat serotonin transporter 
1 (rSRT1) reduced rSRT1 transport activity [117]. Replenishing membrane steroid content 
with cholesterol, but not with ergosterol, 5-cholestene or pregnenolone restored the transport 
activity, suggesting a specific interaction of cholesterol with this transporter. Depletion of 
cholesterol from HEK293 cells expressing rat NTCP (SLC10A1) led to an increased 
taurocholate uptake by the latter [118]. This suggests that this transporter is modulated by 
membrane cholesterol content. A caveat remains as in the same paper the subcellular 
localization of NTCP was altered depending on the cholesterol content, with a stronger 
membrane fluorescence after cholesterol depletion. Own unpublished data show that the 
transport activity of rNTCP expressed in cholesterol poor insect Sf9 cells decreases with 
addition of cholesterol, which is opposite to the published finding. Interestingly, the highly 
homologous intestinal bile salt transporter ASBT (SLC10A2), if expressed in HEK293 cells 
was inhibited by cholesterol depletion [119]. Currently, it remains unclear whether the 




related transporters or whether they are due to technical issues. The finding with NTCP is 
reminiscent of a study of the Glucose transporter GLUT1 expressed in M07e cells, where 
cholesterol depletion leads to a translocation of GLUT1 to the plasma membrane accompanied 
by an increased D-glucose transport activity [120]. This example shows that modulation of 
plasma membrane cholesterol content in cells may not only affect the function of membrane 
transporters but also the subcellular localization of transporters. Any altered expression level 
at the plasma membrane will lead to altered transport rates. 
 
If HEK293 cells expressing the neutral amino acid transporter LAT1 (SLC7A5) are depleted 
in cholesterol, the Vmax of L-DOPA transport is decreased, whereas the Km remains unchanged 
[121]. Based on results obtained from LAT1 purification in the presence and absence of 
cholesterol and in analogy to DAT1 and SERT1, the authors concluded that the function of 
LAT1 critically depends on tightly bound cholesterol molecules. Similarly, the transport 
activity of OCT2 (SLC22A2) expressed in HEK293 cells was reduced after cholesterol 
depletion [122]. In addition, cholesterol depletion shifted OCT2-mediated transport of 1-
methyl-4-phenylpyridinium transport from allosteric kinetics to Michaelis-Menten kinetics in 
this study. To gain more insight on the functional consequences of tightly bound cholesterol 
on SERT1, this transporter was expressed in HEK293-MSR cells [123]. In a binding assay, 
cholesterol depletion shifted the conformation of SERT1 towards a more inward-facing 
conformation. 
 
Cardiolipin is a dimeric anionic phospholipid and is in eukaryotes almost exclusively found in 
the inner mitochondrial membrane [124]. It could be demonstrated in genetically modified 
yeast that cardiolipin is essential for the stability and function of the mitochondrial Ca2+ 
uniporter [125]. This role of cardiolipin is further supported by the clinical manifestation of the 
Barth syndrome, displaying among others with cardiomyopathy and skeletal muscle myopathy. 
Barth syndrome is an X-linked disorder with an inherited defect in the biosynthesis of 
cardiolipin [126]. 
 
Like other transmembrane proteins, ion channels are also modulated by bulk lipid composition 
of membranes. With the rapid progress made by cryo-EM structure determination, 
investigation of the lipid interaction with channels as wells as other transport proteins is now 




lipids and these areas are rapidly moving together, as outlined by a series of recent overviews 
[127-133] 
 
In summary, experiments manipulating bulk membrane lipid composition either in cells or 
when reconstituting transporters into proteoliposomes have provided ample evidence that 
(bulk) membrane lipid composition modulates the activity and properties of transport proteins. 
This effect is not restricted to the lipid class but also, in the case of phospholipids, to acyl chain 
composition. It is important to note that the effect of cholesterol on transporter activity may be 
complex. The cholesterol (sterol) to lipid ratio affects lipid dynamics in membranes [134, 135]. 
However, for some transporters, an alteration of activity was not observed for all sterols tested, 
but was found to be sterol specific. This implies that in addition to alterations of membrane 
lipid dynamics a specific interaction of sterols with transporters is relevant, which was, indeed, 
observed in cryo-EM studies. Having now the first high resolution structures of lipid 
transporters [136, 137] or translocators [53, 138-140], it will be interesting to see whether 
structural features of these lipid transporters reveal information on structural requirements for 
the tight binding of annular lipids in transmembrane transporters as well as other 
transmembrane proteins. Needless to say that such information will also be obtained once the 
resolution of membrane proteins can be further increased. 
 
Disease-mediated lipid changes 
In Western society, overweight and obesity are of epidemic extent and rising [141]. This 
condition may lead to nonalcoholic fatty liver disease [142]. Nonalcoholic fatty liver disease 
is a liver pathology ranging from steatosis to steatohepatitis, which may progress to fibrosis 
and ultimately cirrhosis [143]. As it is difficult obtaining human liver tissue for analytical and 
functional studies, the number of studies using human plasma samples clearly exceeds the 
number of studies working with human liver tissue [142]. It was for example observed in liver 
biopsies that the ratio of free cholesterol to phosphatidylcholine is significantly increased in 
patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis [144]. Lipidomic 
analysis of liver biopsies from patients with nonfatty liver disease demonstrated that different 
stages can be discriminated [145]. A lipidomic analysis in conjunction with a random forests 
based machine learning of liver biopsies from patients with nonalcoholic fatty liver disease and 
from patients with nonalcoholic steatohepatitis led to the identification of a specific lipid 
signature of 32 lipids allowing the discrimination of the different forms of fatty liver diseases 




complex, some phospholipids tend to be increased and some tend to be decreased in patients 
relative to control samples. In addition, the lipid composition between non-steatotic and 
steatotic tissue areas is very different [147]. A zonal differentiation of lipid patterns is not only 
found in diseased human livers but also in biopsies from healthy individuals [148]. It was 
shown that the clearance of mebrofenin is significantly reduced in patients with nonalcoholic 
steatohepatitis in comparison to control subjects [149]. Mebrofenin is a substrate for organic 
anion uptake transporters and of MRP2 [150, 151]. A quantitative proteomic analysis of human 
liver biopsies showed a significantly lower expression of OATP1B1, OATP1B3 as well as 
MRP2 [152]. This example shows that the impact of altered membrane lipid composition in 
diseased states on transporter function is not easily delineated from human studies, as in parallel 
to altering membrane lipid composition, diseases also affect the protein expression levels of 
transporters. So far no common pattern on altered transport protein expression in biopsies from 
humans with different forms and degrees of liver diseases has so far not merged [153]. The 
interpretation of human pharmacokinetic studies at the level of molecular mechanisms is 
further complicated as not only transporters, but also drug metabolizing enzymes display 
altered protein expression in different forms of nonalcoholic fatty liver disease [154]. 
 
Statins are inhibitors of cholesterol biosynthesis and are widely prescribed drugs for the 
treatment of patients with hypercholesterolemia. Statins are generally well tolerated but are 
known to lead to myopathy as the most common adverse event [155]. The exact molecular 
mechanism leading to statin-induced myopathy is still discussed [156]. Biophysical changes of 
membrane properties may be involved. Treatment of HEK293T cells with simvastatin led to a 
reduction of the cholesterol to phospholipid ratio, but did not change membrane fluidity [157]. 
This study did however observe an increase in phosphatidylethanolamine and its plasmalogen. 
To what extent this finding can be extrapolated to myocytes remains open. It is accepted that 
statins may affect plasma membrane microdomains (also called lipid rafts) [158]. Treatment of 
patients with statins was found to cause a reduction of erythrocyte and platelet membrane 
cholesterol and an increased activity of (Na++K+)-ATPase [159-161]. However, conflicting 
data on cholesterol content of erythrocytes have been published [162]. 
 
Viral infections, for example with hepatitis viruses, affect over two billion people globally 
[163]. Hepatitis viruses are one example of many different viruses affecting not only protein 
expression but also lipid homeostasis including membrane lipid composition after host cell 




transporters. Viral infection has also been demonstrated to alter transporter expression, e.g. in 
liver [165], but it should be kept in mind that transporter expression shows a large 
interindividual variability [166]. 
 
Conclusion 
Technical advances in lipidomics as well in the determination of structures of membrane 
proteins have provided convincing evidence for an important role of membrane lipids in 
affecting both the structure and the function of transport proteins. Evidence is emerging that 
changes in lipid composition in vivo (either due to diseases or to dietary habits) may have 
consequences on the disposition of drugs. It remains challenging to differentiate between 
altered transporter numbers and altered transporter function, as quantification of transporters 
requires taking biopsies from the organs of interest, which is generally not possible with 
humans. As erythrocytes also express transport proteins [167, 168] and are easily available 
from patients, transport protein levels could be determined by quantitative, targeted 
proteomics. Such a surrogate approach might be useful for an estimation of transporter 
expression levels in individual patients. To the best of our knowledge, such an approach has so 
far not been validated in a study involving humans. In parallel to in vivo transport 
(pharmacokinetics) quantification, the number of transporter substrates suitable for imaging in 
humans is constantly increasing [169, 170]. Combing in vivo methods with in vitro experiments 
will certainly advance our knowledge on the impact of membrane lipid composition and of 
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Legends to figures: 
 
Figure 1: Schematic view of membrane flow in eukaryotic cells. Red arrows indicate flux of 
membrane vesicles from the endoplasmic reticulum towards the plasma membrane. Blue 
arrows indicate flux of membrane vesicles from the cell membrane towards the endoplasmic 
reticulum. These routes are not intended to imply a direct route of individual vesicles through 
the entire pathway. Green arrows indicate flux of vesicles in the endocytic compartment. 
 
Figure 2: Steady state distribution of lipids in major cellular organelles. PC: 
phosphatidylcholine, PE: phosphatidylethanolamine; PI: phosphatidylinositol, PS: 
phosphatidylserine, R: remaining lipids. The data are taken from [6, 171]. 
 
Figure 3: Steady cholesterol distribution of cholesterol in major cellular organelles. The data 
are taken from [171] 
 
Figure 4: Schematic vies of lipid with transporters. Lipids can interact with transporters as 
tightly bound lipids (marked in blue) or via the bulk lipid composition (blue arrow). 
 
Figure 5: Phospholipids and cholesterol bound to ABCB1 (A) and to ABCG2 (B). The structures 
of the transporters are shown either as electrostatic surface potentials (ESPs) or as ribbon 
diagrams. ESPs are colored for negative partial charges red and blue for positive partial 
charges. Tightly bound cholesterol molecules and phosphatidylethanolamine are shown in 
sphere representation. Cholesterol is colored green, whereas phosphatidylethanolamine is 
colored yellow. The structures are taken from [45] for MDR1 and from [51] for ABCG2. 
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